Ablation Equipments - Medical Devices Pipeline Assessment, 2018

Ablation Equipments - Medical Devices Pipeline Assessment, 2018

Summary

GlobalDatas Medical Devices sector report, Ablation Equipments - Medical Devices Pipeline Assessment, 2018" provides an overview of Ablation Equipments currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ablation Equipments pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalDatas team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Ablation Equipments under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry.

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Ablation Equipments under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date.


1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 9
2.1 Ablation Equipments Overview 9
3 Products under Development 10
3.1 Ablation Equipments - Pipeline Products by Stage of Development 10
3.2 Ablation Equipments - Pipeline Products by Territory 11
3.3 Ablation Equipments - Pipeline Products by Regulatory Path 12
3.4 Ablation Equipments - Pipeline Products by Estimated Approval Date 13
3.5 Ablation Equipments - Ongoing Clinical Trials 14
4 Ablation Equipments - Pipeline Products under Development by Companies 15
4.1 Ablation Equipments Companies - Pipeline Products by Stage of Development 15
4.2 Ablation Equipments - Pipeline Products by Stage of Development 16
5 Ablation Equipments Companies and Product Overview 17
5.1 AngioDynamics Inc Company Overview 17
5.1.1 AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 17
5.2 Avenda Health Inc Company Overview 32
5.2.1 Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview 32
5.3 CPSI Biotech Company Overview 33
5.3.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 33
5.4 Creo Medical Ltd. Company Overview 35
5.4.1 Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 35
5.5 Deneb Medical SL Company Overview 36
5.5.1 Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview 36
5.6 Fractyl Laboratories Inc Company Overview 37
5.6.1 Fractyl Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 37
5.7 Harmonic Medical Inc Company Overview 41
5.7.1 Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 41
5.8 HistoSonics Inc Company Overview 44
5.8.1 HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.9 Hospital for Special Surgery Company Overview 45
5.9.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 45
5.10 Imricor Medical Systems Inc Company Overview 46
5.10.1 Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 46
5.11 Innoblative Designs, Inc. Company Overview 49
5.11.1 Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49
5.12 Integra LifeSciences Holdings Corp Company Overview 50
5.12.1 Integra LifeSciences Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview 50
5.13 Intratherm LLC (Inactive) Company Overview 52
5.13.1 Intratherm LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52
5.14 Massachusetts Institute of Technology Company Overview 53
5.14.1 Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 53
5.15 Medtronic plc Company Overview 54
5.15.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 54
5.16 Memorial Sloan Kettering Cancer Center Company Overview 56
5.16.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 56
5.17 Mirabilis Medical Inc Company Overview 57
5.17.1 Mirabilis Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 57
5.18 Pulse Biosciences Inc Company Overview 60
5.18.1 Pulse Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 60
5.19 Southern Illinois University Carbondale Company Overview 61
5.19.1 Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview 61
5.20 Thermedical Inc Company Overview 62
5.20.1 Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview 62
5.21 TransEnterix Inc Company Overview 63
5.21.1 TransEnterix Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.22 University of California San Francisco Company Overview 64
5.22.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 64
5.23 University of Texas at Austin Company Overview 65
5.23.1 University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview 65
5.24 University of Wisconsin-Stout Company Overview 66
5.24.1 University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview 66
6 Ablation Equipments- Recent Developments 67
6.1 Jul 11, 2018: AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results 67
6.2 Jul 10, 2018: Stryker announces organizational changes 68
6.3 Jul 05, 2018: SonaCare reports long-term results of HIFU therapy for prostate cancer 69
6.4 Jun 23, 2018: Fractyl Announces Presentation of Key Scientific Research at ADA 2018 Indicating That Modern Diets Durably Alter Duodenal Lining, Highlighting the Intestines Role in Type 2 Diabetes and NASH 69
6.5 Jun 14, 2018: HSS Hip and Knee Surgeon Bradford Waddell, MD, Named Chair of Young Arthroplasty Group 71
6.6 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 71
7 Appendix 139
7.1 Methodology 139
7.2 About GlobalData 142
7.3 Contact Us 142
7.4 Disclaimer 142

List Of Tables


Table 1: Ablation Equipments - Pipeline Products by Stage of Development 11
Table 2: Ablation Equipments - Pipeline Products by Territory 12
Table 3: Ablation Equipments - Pipeline Products by Regulatory Path 13
Table 4: Ablation Equipments - Pipeline Products by Estimated Approval Date 14
Table 5: Ablation Equipments - Ongoing Clinical Trials 15
Table 6: Ablation Equipments Companies - Pipeline Products by Stage of Development 16
Table 7: Ablation Equipments - Pipeline Products by Stage of Development 17
Table 8: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 18
Table 9: NanoKnife 3.0 - Product Status 18
Table 10: NanoKnife 3.0 - Product Description 19
Table 11: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status 19
Table 12: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description 19
Table 13: NanoKnife System - Pancreatic Cancer - Product Status 20
Table 14: NanoKnife System - Pancreatic Cancer - Product Description 20
Table 15: NanoKnife System - Prostate Cancer - Product Status 20
Table 16: NanoKnife System - Prostate Cancer - Product Description 21
Table 17: AngioDynamics Inc - Ongoing Clinical Trials Overview 22
Table 18: NanoKnife System - Prostate Cancer - Efficacy and Safety Assessment of Nanoknife (AngyoDynamics, USA) for Irreversible Electroporation (IRE) of Localized Prostate Cancer 24
Table 19: NanoKnife System - Prostate Cancer - Focal Irreversible Electroporation as Salvage Treatment in Radio-recurrent Prostate Cancer: A Prospective Multicenter Pilot Study 24
Table 20: NanoKnife System - Prostate Cancer - Irreversible Electroporation (IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial 24
Table 21: NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer 25
Table 22: NanoKnife System - Prostate Cancer - Registry of Irreversible Electroporation for the Ablation of Prostate Cancer with Use of Nanoknife Device; A Multi-center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety 25
Table 23: NanoKnife System - Pancreatic Cancer - A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer 26
Table 24: NanoKnife System - Pancreatic Cancer - A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas 26
Table 25: NanoKnife System - Pancreatic Cancer - Assessing Optimal Treatment Settings for the Ablation of Locally Advanced Pancreatic Cancer with CT-guided Percutaneous Irreversible Electroporation (ANTILOPE): A Randomized Feasibility Study 26
Table 26: NanoKnife System - Pancreatic Cancer - Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival after Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation: CROSSFIRE Trial 27
Table 27: NanoKnife System - Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study 27
Table 28: NanoKnife System - Pancreatic Cancer - Impact of Irreversible Electroporation on Quality of Life for Patients with Locally Advanced Pancreatic Cancer 27
Table 29: NanoKnife System - Pancreatic Cancer - Interest of Irreversible Electroporation in the Treatment of Pancreatic Adenocarcinoma 28
Table 30: NanoKnife System - Pancreatic Cancer - IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer 28
Table 31: NanoKnife System - Pancreatic Cancer - Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial 28
Table 32: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder 29
Table 33: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers 29
Table 34: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial: COLDFIRE-2 Study 29
Table 35: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer 30
Table 36: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome 30
Table 37: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE) 30
Table 38: NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial 31
Table 39: NanoKnife 3.0 - The Safety and Feasibility of Irreversible Electroporation for the Ablation of Small Renal Masses 32
Table 40: Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview 33
Table 41: Fiber - Optic Laser - Product Status 33
Table 42: Fiber - Optic Laser - Product Description 33
Table 43: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 34
Table 44: Pressurized Sub-Cooled Nitrogen System - Product Status 34
Table 45: Pressurized Sub-Cooled Nitrogen System - Product Description 34
Table 46: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Status 34
Table 47: Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Description 35
Table 48: Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 36
Table 49: Flexible Ablation System - Product Status 36
Table 50: Flexible Ablation System - Product Description 36
Table 51: Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview 37
Table 52: BoneCut Collaborative Robot - Product Status 37
Table 53: BoneCut Collaborative Robot - Product Description 37
Table 54: Fractyl Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 38
Table 55: Revita DMR System - Product Status 38
Table 56: Revita DMR System - Product Description 38
Table 57: Fractyl Laboratories Inc - Ongoing Clinical Trials Overview 39
Table 58: Revita DMR System - Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study 40
Table 59: Revita DMR System - Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes 40
Table 60: Revita DMR System - Evaluation of the Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D) 40
Table 61: Revita DMR System - Multicenter Clinical Trial of Revita DMR Procedure in Patients with Diabetes 41
Table 62: Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 42
Table 63: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Status 42
Table 64: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Description 42
Table 65: Harmonic Medical Inc - Ongoing Clinical Trials Overview 43
Table 66: Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - MRI-guided High Intensity Focused Ultrasound Ablation of Leiomyomas. Single Arm, Feasibility Study Using the Symphony - MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas. 44
Table 67: HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview 45
Table 68: Vortx RX - Product Status 45
Table 69: Vortx RX - Product Description 45
Table 70: Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 46
Table 71: Radiofrequency Ablation Device - Product Status 46
Table 72: Radiofrequency Ablation Device - Product Description 46
Table 73: Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 74: Vision MR Ablation Catheter - Product Status 47
Table 75: Vision MR Ablation Catheter - Product Description 47
Table 76: Imricor Medical Systems Inc - Ongoing Clinical Trials Overview 48

List Of Figures


Figure 1: Ablation Equipments - Pipeline Products by Stage of Development 11
Figure 2: Ablation Equipments - Pipeline Products by Territory 12
Figure 3: Ablation Equipments - Pipeline Products by Regulatory Path 13
Figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date 14
Figure 5: Ablation Equipments - Ongoing Clinical Trials 15

2018 Global Cardiac Ablation Device Industry Report - History, Present and Future

The global market size of Cardiac Ablation Device is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

USD 4000 View Report

Global Ablation Equipments Market Research Report 2018

Ablation Equipments Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the

USD 2850 View Report

Global Ablation Equipments Market Research Report 2018

Ablation Equipments Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the

USD 2850 View Report

Endoscopic Electrosurgery Equipments - Medical Devices Pipeline Assessment, 2018

Endoscopic Electrosurgery Equipments - Medical Devices Pipeline Assessment, 2018The Medical Devices sector report, Endoscopic Electrosurgery Equipments - Medical Devices Pipeline Assessment, 2018 provides an overview of Endoscopic Electrosurgery Equipments currently

USD 2500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available